



(11) **EP 2 062 571 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 9/107 (2006.01) **A61K 9/48** (2006.01)
A61K 47/10 (2006.01) **A61K 47/26** (2006.01)
A61K 47/44 (2006.01)

(48) Corrigendum issued on:
19.12.2012 Bulletin 2012/51

(45) Date of publication and mention
of the grant of the patent:
14.11.2012 Bulletin 2012/46

(21) Application number: **08020342.5**

(22) Date of filing: **21.11.2008**

(54) **Self-emulsifying pharmaceutical composition with enhanced bioavailability**

Selbstemulgierende pharmazeutische Zusammensetzung mit verbesserter Bioverfügbarkeit

Composition pharmaceutique à auto-émulsion avec une biodisponibilité améliorée

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT
RO SE SI SK TR**

• **Hsu, Chang-Shan**
Taipei 114,
Taiwan,
Taiwan R.O.C. (TW)

(30) Priority: **21.11.2007 US 944239**

(74) Representative: **Becker Kurig Straus**
Bavariastrasse 7
80336 München (DE)

(43) Date of publication of application:
27.05.2009 Bulletin 2009/22

(73) Proprietor: **INNOPHARMAX INC.**
Taipei 11492 (TW)

(56) References cited:
EP-A- 0 274 870 EP-A- 0 985 412
WO-A-98/33512 WO-A-98/40094
FR-A- 2 775 596

(72) Inventors:
• **Hao, Wei-Hua**
Taipei 114,
Taiwan, R.O.C. (TW)
• **Wang, Jong-Jing**
Taipei 114,
Taiwan, R.O.C. (TW)

Remarks:

The file contains technical information submitted after
the application was filed and not included in this
specification

EP 2 062 571 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).